VINC
Vincerx Pharma, Inc.
Price Chart
Latest Quote
$0.01
+0.00 (+0.00%)
Current Price
| Previous Close | $0.01 |
| Open | $0.01 |
| Day High | $0.01 |
| Day Low | $0.01 |
| Volume | 22 |
Stock Information
| Shares Outstanding | 5.23M |
| Cash Equivalents | $4.44M |
| Net Income | $-22.64M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $68K |
| EPS (TTM) | $-5.79 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-4.37M |
| Income | $-22.64M |
| Book/sh | $0.40 |
| Cash/sh | $0.85 |
| Employees | 12 |
Financial Ratios
| Quick Ratio | 1.69 |
| Current Ratio | 1.79 |
Returns & Margins
| ROA | -197.53% |
| ROE | -3136.43% |
Ownership
| Insider Ownership | 4.11% |
| Institutional Ownership | 5.25% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.02 |
| P/B | 0.03 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.01 |
| SMA50 | $0.01 |
| SMA200 | $0.02 |
| RSI | 50.00 |
| ATR | 0.0006 |
| Shares Float | 4.75M |
| Short Float | 2.72% |
| Short Ratio | 0.10 |
| Volatility | 1.46 |
Performance History
| Week | +0.00% |
| Month | +0.00% |
| Quarter | +0.00% |
| 6 Months | +8.33% |
| YTD | +0.00% |
| Year | -74.00% |
| 3 Years | -99.96% |
| 5 Years | -100.00% |
| 10 Years | -99.99% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-03 | $0.01 | 0 |
| 2026-06-02 | $0.01 | 1,000 |
| 2026-06-01 | $0.01 | 700 |
| 2026-05-29 | $0.01 | 300 |
| 2026-05-28 | $0.01 | 5,600 |
| 2026-05-27 | $0.01 | 300 |
| 2026-05-26 | $0.01 | 17,800 |
| 2026-05-22 | $0.01 | 2,700 |
| 2026-05-21 | $0.01 | 200 |
| 2026-05-20 | $0.01 | 0 |
| 2026-05-19 | $0.01 | 0 |
| 2026-05-18 | $0.01 | 900 |
| 2026-05-15 | $0.02 | 0 |
| 2026-05-14 | $0.02 | 2,800 |
| 2026-05-13 | $0.01 | 0 |
| 2026-05-12 | $0.01 | 0 |
| 2026-05-11 | $0.01 | 300 |
| 2026-05-08 | $0.01 | 0 |
| 2026-05-07 | $0.01 | 200 |
| 2026-05-06 | $0.01 | 6,300 |
| 2026-05-05 | $0.01 | 0 |
| 2026-05-04 | $0.01 | 2,200 |
About Vincerx Pharma, Inc.
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and provides CellTrapper technology for use in reduction of payload cellular permeability. The company develops VIP943, an antibody drug conjugate in Phase 1 dose-escalation study for relapsed/refractory acute myeloid leukemia, higher-risk MDS, and B-cell acute lymphoblastic leukemia; VIP236, an SMDC, which is in Phase 1 dose-escalation study for the treatment of patients with advanced or metastatic solid tumors; and VIP924, an anti-CXCR5 ADC that leverages the same effector chemistry in preclinical studies for b-cell malignancies. It has a collaboration with the National Institutes of Health for the Phase 1 dose-escalation of enitociclib, a highly selective cyclin-dependent kinase 9 inhibitor. The company was formerly known as Vincera Pharma, Inc. and changed its name to Vincerx Pharma, Inc. in January 2021. Vincerx Pharma, Inc. was founded in 2019 and is headquartered in San Mateo, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on VINC.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $31,463,000 | $42,609,000 | $68,722,000 | $62,656,000 |
| Other Income Expense | $917,000 | $1,201,000 | $5,074,000 | $23,350,000 |
| Other Non Operating Income Expenses | $734,000 | $1,248,000 | $1,240,000 | $-8,000 |
| Net Non Operating Interest Income Expense | $472,000 | $1,251,000 | $664,000 | $0 |
| Operating Expense | $31,463,000 | $42,609,000 | $68,722,000 | $62,656,000 |
| General And Administrative Expense | $15,977,000 | $13,636,000 | $18,885,000 | $22,575,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-30,074,000 | $-40,157,000 | $-62,984,000 | $-39,306,000 |
| Net Interest Income | $472,000 | $1,251,000 | $664,000 | $0 |
| Interest Income | $472,000 | $1,251,000 | $664,000 | $0 |
| Normalized Income | $-30,257,000 | $-40,110,000 | $-66,818,000 | $-62,664,000 |
| Net Income From Continuing And Discontinued Operation | $-30,074,000 | $-40,157,000 | $-62,984,000 | $-39,306,000 |
| Total Operating Income As Reported | $-31,463,000 | $-42,609,000 | $-71,191,000 | $-62,656,000 |
| Net Income Common Stockholders | $-30,074,000 | $-40,157,000 | $-62,984,000 | $-39,306,000 |
| Net Income | $-30,074,000 | $-40,157,000 | $-62,984,000 | $-39,306,000 |
| Net Income Including Noncontrolling Interests | $-30,074,000 | $-40,157,000 | $-62,984,000 | $-39,306,000 |
| Net Income Continuous Operations | $-30,074,000 | $-40,157,000 | $-62,984,000 | $-39,306,000 |
| Pretax Income | $-30,074,000 | $-40,157,000 | $-62,984,000 | $-39,306,000 |
| Interest Income Non Operating | $472,000 | $1,251,000 | $664,000 | $0 |
| Operating Income | $-31,463,000 | $-42,609,000 | $-68,722,000 | $-62,656,000 |
| Special Income Charges | - | $0 | $-2,469,000 | $0 |
| Per Share | ||||
| Diluted EPS | $-15.85 | $-37.72 | $-62.20 | $-45.80 |
| Basic EPS | $-15.85 | $-37.72 | $-62.20 | $-45.80 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-30,556,000 | $-41,647,000 | $-71,617,000 | $-85,674,000 |
| Total Unusual Items | $183,000 | $-47,000 | $3,834,000 | $23,358,000 |
| Total Unusual Items Excluding Goodwill | $183,000 | $-47,000 | $3,834,000 | $23,358,000 |
| Reconciled Depreciation | $1,090,000 | $915,000 | $939,000 | $340,000 |
| EBITDA (Bullshit earnings) | $-30,373,000 | $-41,694,000 | $-67,783,000 | $-62,316,000 |
| EBIT | $-31,463,000 | $-42,609,000 | $-68,722,000 | $-62,656,000 |
| Diluted Average Shares | $1,898,000 | $1,065,000 | $1,051,450 | $858,800 |
| Basic Average Shares | $1,898,000 | $1,065,000 | $1,051,450 | $858,800 |
| Diluted NI Availto Com Stockholders | $-30,074,000 | $-40,157,000 | $-62,984,000 | $-39,306,000 |
| Gain On Sale Of Security | $183,000 | $-47,000 | $6,303,000 | $23,358,000 |
| Research And Development | $15,486,000 | $28,973,000 | $49,837,000 | $40,081,000 |
| Selling General And Administration | $15,977,000 | $13,636,000 | $18,885,000 | $22,575,000 |
| Other Gand A | $15,977,000 | $13,636,000 | $18,885,000 | $22,575,000 |
| Restructuring And Mergern Acquisition | - | $0 | $2,469,000 | $0 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $2,724,000 | $11,222,000 | $47,668,000 | $100,321,000 |
| Total Assets | $8,005,000 | $18,217,000 | $59,286,000 | $117,676,000 |
| Total Non Current Assets | $1,595,000 | $3,484,000 | $3,322,000 | $5,835,000 |
| Other Non Current Assets | $1,595,000 | $1,158,000 | $81,000 | $1,653,000 |
| Current Assets | $6,410,000 | $14,733,000 | $55,964,000 | $111,841,000 |
| Other Current Assets | $49,000 | $377,000 | $369,000 | $95,000 |
| Restricted Cash | $79,000 | $72,000 | $70,000 | $105,000 |
| Prepaid Assets | $254,000 | $458,000 | $1,694,000 | $182,000 |
| Receivables | $1,041,000 | $1,044,000 | $1,372,000 | $0 |
| Other Receivables | $1,041,000 | $1,044,000 | $1,372,000 | - |
| Cash Cash Equivalents And Short Term Investments | $4,987,000 | $12,782,000 | $52,459,000 | $111,459,000 |
| Cash And Cash Equivalents | $4,987,000 | $12,782,000 | $11,663,000 | $111,459,000 |
| Taxes Receivable | - | $250,000 | $0 | - |
| Cash Financial | - | - | - | $111,459,000 |
| Debt | ||||
| Total Debt | $0 | $2,502,000 | $3,436,000 | $4,174,000 |
| Long Term Debt And Capital Lease Obligation | $0 | $1,340,000 | $2,412,000 | $3,436,000 |
| Current Debt And Capital Lease Obligation | - | $1,162,000 | $1,024,000 | $738,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $5,281,000 | $6,995,000 | $11,618,000 | $17,355,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $1,390,000 | $2,462,000 | $3,436,000 |
| Current Liabilities | $5,281,000 | $5,605,000 | $9,156,000 | $13,919,000 |
| Other Current Liabilities | $8,000 | $191,000 | $144,000 | $6,447,000 |
| Payables And Accrued Expenses | $5,273,000 | $4,252,000 | $5,946,000 | $4,220,000 |
| Payables | $2,029,000 | $2,497,000 | $4,065,000 | $2,019,000 |
| Accounts Payable | $2,029,000 | $2,497,000 | $4,065,000 | $2,019,000 |
| Other Non Current Liabilities | - | $50,000 | $50,000 | - |
| Equity | ||||
| Common Stock Equity | $2,724,000 | $11,222,000 | $47,668,000 | $100,321,000 |
| Total Equity Gross Minority Interest | $2,724,000 | $11,222,000 | $47,668,000 | $100,321,000 |
| Stockholders Equity | $2,724,000 | $11,222,000 | $47,668,000 | $100,321,000 |
| Gains Losses Not Affecting Retained Earnings | $119,000 | $8,000 | $-26,000 | $-21,000 |
| Other Equity Adjustments | $119,000 | $8,000 | $-26,000 | $-21,000 |
| Retained Earnings | $-189,186,000 | $-159,112,000 | $-118,955,000 | $-55,971,000 |
| Other | ||||
| Ordinary Shares Number | $2,239,580 | $1,070,375 | $1,062,144 | $1,052,878 |
| Share Issued | $2,239,580 | $1,070,375 | $1,062,144 | $1,052,878 |
| Tangible Book Value | $2,724,000 | $11,222,000 | $47,668,000 | $100,321,000 |
| Invested Capital | $2,724,000 | $11,222,000 | $47,668,000 | $100,321,000 |
| Working Capital | $1,129,000 | $9,128,000 | $46,808,000 | $97,922,000 |
| Capital Lease Obligations | $0 | $2,502,000 | $3,436,000 | $4,174,000 |
| Total Capitalization | $2,724,000 | $11,222,000 | $47,668,000 | $100,321,000 |
| Additional Paid In Capital | $191,791,000 | $170,326,000 | $166,647,000 | $156,311,000 |
| Capital Stock | $0 | $0 | $2,000 | $2,000 |
| Common Stock | $0 | $0 | $2,000 | $2,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $0 | $1,340,000 | $2,412,000 | $3,436,000 |
| Current Capital Lease Obligation | $0 | $1,162,000 | $1,024,000 | $738,000 |
| Current Accrued Expenses | $3,244,000 | $1,755,000 | $1,881,000 | $2,201,000 |
| Net PPE | $0 | $2,326,000 | $3,241,000 | $4,182,000 |
| Accumulated Depreciation | $0 | $-131,000 | $-79,000 | $-25,000 |
| Gross PPE | $0 | $2,457,000 | $3,320,000 | $4,207,000 |
| Machinery Furniture Equipment | $0 | $256,000 | $256,000 | $258,000 |
| Treasury Shares Number | - | $0 | - | - |
| Pensionand Other Post Retirement Benefit Plans Current | - | $0 | $2,042,000 | $2,514,000 |
| Other Properties | - | $2,201,000 | $3,064,000 | $3,949,000 |
| Other Short Term Investments | - | $0 | $40,796,000 | $0 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-26,127,000 | $-40,453,000 | $-59,604,000 | $-38,660,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-26,127,000 | $-40,453,000 | $-59,604,000 | $-33,402,000 |
| Cash Flow From Continuing Operating Activities | $-26,127,000 | $-40,453,000 | $-59,604,000 | $-33,402,000 |
| Operating Gains Losses | $-183,000 | $47,000 | $-6,303,000 | $-23,358,000 |
| Investing Activities | ||||
| Investing Cash Flow | $212,000 | $41,500,000 | $-40,578,000 | $-5,258,000 |
| Cash Flow From Continuing Investing Activities | $212,000 | $41,500,000 | $-40,578,000 | $-5,258,000 |
| Capital Expenditure Reported | - | - | $0 | $-258,000 |
| Capital Expenditure | - | - | - | $-5,258,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $17,874,000 | $0 | $0 | $47,431,000 |
| Financing Cash Flow | $17,992,000 | $114,000 | $280,000 | $88,453,000 |
| Cash Flow From Continuing Financing Activities | $17,992,000 | $114,000 | $280,000 | $88,453,000 |
| Net Common Stock Issuance | $17,874,000 | $0 | $0 | $47,431,000 |
| Common Stock Issuance | $17,874,000 | $0 | $0 | $47,431,000 |
| Other | ||||
| Interest Paid Supplemental Data | $0 | $0 | $0 | $25,000 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | - |
| End Cash Position | $5,066,000 | $12,854,000 | $11,733,000 | $111,564,000 |
| Beginning Cash Position | $12,854,000 | $11,733,000 | $111,564,000 | $61,792,000 |
| Effect Of Exchange Rate Changes | $135,000 | $-40,000 | $71,000 | $-21,000 |
| Changes In Cash | $-7,923,000 | $1,161,000 | $-99,902,000 | $49,793,000 |
| Proceeds From Stock Option Exercised | $118,000 | $114,000 | $280,000 | $41,022,000 |
| Net Investment Purchase And Sale | $212,000 | $41,500,000 | $-40,578,000 | $0 |
| Sale Of Investment | $11,675,000 | $53,321,000 | $2,400,000 | $0 |
| Purchase Of Investment | $-11,463,000 | $-11,821,000 | $-42,978,000 | $0 |
| Change In Working Capital | $-178,000 | $-4,191,000 | $-1,020,000 | $5,609,000 |
| Change In Other Working Capital | $-50,000 | - | $50,000 | - |
| Change In Other Current Liabilities | $-1,162,000 | $-934,000 | $-738,000 | $-90,000 |
| Change In Other Current Assets | $-519,000 | $-1,077,000 | $1,372,000 | $-1,571,000 |
| Change In Payables And Accrued Expense | $1,021,000 | $-3,736,000 | $1,254,000 | $6,229,000 |
| Change In Accrued Expense | $1,489,000 | $-2,168,000 | $208,000 | $4,715,000 |
| Change In Payable | $-468,000 | $-1,568,000 | $1,046,000 | $1,514,000 |
| Change In Account Payable | $-468,000 | $-1,568,000 | $1,046,000 | $1,528,000 |
| Change In Prepaid Assets | $532,000 | $1,228,000 | $-3,158,000 | $1,041,000 |
| Change In Receivables | $0 | $328,000 | $200,000 | - |
| Other Non Cash Items | $-44,000 | - | - | - |
| Stock Based Compensation | $3,473,000 | $3,563,000 | $10,056,000 | $23,313,000 |
| Amortization Of Securities | $-211,000 | $-630,000 | $-292,000 | $0 |
| Depreciation Amortization Depletion | $1,090,000 | $915,000 | $939,000 | $340,000 |
| Depreciation And Amortization | $1,090,000 | $915,000 | $939,000 | $340,000 |
| Depreciation | $1,090,000 | $915,000 | $939,000 | $340,000 |
| Gain Loss On Investment Securities | $-183,000 | $47,000 | $-6,303,000 | $-23,358,000 |
| Net Income From Continuing Operations | $-30,074,000 | $-40,157,000 | $-62,984,000 | $-39,306,000 |
| Net Intangibles Purchase And Sale | - | - | $0 | $-5,000,000 |
| Purchase Of Intangibles | - | - | $0 | $-5,000,000 |
Fetched: 2026-02-02